At the upcoming Annual General Meeting (AGM) on April 25, Bidiphar (HOSE: DBD) will present a share issuance plan to concentrate resources on key infrastructure projects.
Capital Raising and Investment Plans:
-
Private Placement: The company plans to issue 23.3 million shares to a maximum of five professional investors. At a minimum price of 50,000 VND/share, the total capital raised is estimated at 1,165 billion VND.
-
Use of Proceeds: All funds will be allocated to two factory projects: a Small Volume Sterile Drug Factory and an OSD Non-Betalactam Factory.
-
ESOP Policy: Bidiphar also intends to issue 1.5 million ESOP shares to employees, contingent upon the progress of obtaining GMP-EU certification for the new facilities.
Financial Overview and 2026 Targets: In 2025, the company recorded a revenue of 1,865 billion VND and a post-tax profit of 290.7 billion VND (exceeding the profit target by 3%). By year-end, cash and bank deposits surged by 39% to 611 billion VND. Construction-in-progress costs at the Nhon Hoi project also spiked to 505 billion VND.
For 2026, Bidiphar has set the following targets:
-
Revenue: Over 2,100 billion VND (up 7%).
-
Pre-tax Profit: 375 billion VND (up 9%).
-
Dividend: Maintaining a minimum of 20%.
Challenges and Solutions: While benefiting from policies prioritizing domestic drugs, Bidiphar faces pressure from the costs of complying with high-quality standards (GMP-EU) and global raw material price fluctuations. The enterprise aims to accelerate digital transformation via the SAP S/4HANA system and AI applications to optimize labor productivity by an additional 10%.